VP, Novel Asset Advancement

Telix Pharmaceuticals (AMER)

16h•Hybrid

About The Position

The VP, Novel Asset Advancement will serve as the executive asset owner for Telix’s CD66-targeted hematologyoncology programs, with accountability for the end-to-end strategy, advancement, and value realization of TLX66 diagnostic and therapeutic candidates through clinical development and toward registration. The position is responsible for defining and evolving the integrated asset strategy, including business case ownership, development planning, indication prioritization, and investment recommendations, while ensuring alignment with enterprise portfolio priorities. Operating as a senior individual contributor and peer to functional Vice Presidents, this role will lead cross-functional alignment and drive enterprise-level decisions, ensuring the program is strategically positioned, appropriately resourced, and executed to achieve key development, regulatory, and commercial milestones. This role is critical to advancing Telix’s first hematology-oncology product and directly impacts pipeline value, portfolio strategy, and long-term company growth.

Requirements

Advanced degree in life sciences, medicine, pharmacy, or related field required; PhD, MD, or PharmD preferred
15+ years of progressive pharmaceutical or biotechnology experience, including significant experience in drug development and strategic program or asset leadership
Demonstrated experience leading complex, cross-functional development programs or assets, ideally within oncology
Proven ability to own and advance asset strategy, including business case development, development planning, and governance engagement
Strong understanding of global regulatory environments (FDA, EMA, APAC) and their impact on development strategy
Demonstrated success operating as a senior individual contributor influencing executive leadership and cross-functional decision-making
Experience presenting to and influencing executive governance bodies (e.g., executive committees, portfolio boards)
Strong financial and strategic acumen, including investment decision support, scenario planning, and risk management

Nice To Haves

Inclusive mindset: Demonstrate an understanding and appreciation for diversity, and actively work to create an inclusive environment where everyone feels valued and respected
Creativity and innovation: Possess a willingness to think outside the box and come up with unique and creative solutions to challenges
Commitment to excellence: Take pride in your work and consistently strive for excellence in everything you do
Results-oriented: Driven to achieve goals and objectives, with a strong focus on delivering measurable results
Ethical behavior: Act with integrity and demonstrate a commitment to ethical behavior in all interactions with colleagues and stakeholders
Adaptability: Comfortable working in a dynamic environment, able to adjust to changing priorities, and willing to take on new challenges
Strong communication skills: Able to communicate effectively with colleagues and stakeholders at all levels, using clear and concise language
Collaboration: Work effectively as part of a team, actively sharing knowledge and expertise to achieve common goals
Resilience: Demonstrate the ability to bounce back from setbacks and persevere in the face of challenges
Continuous learning: Show a commitment to ongoing learning and professional development, continually seeking out opportunities to expand your knowledge and skills

Responsibilities

Serve as the executive asset owner for Telix’s CD66-targeted hematology-oncology programs, with full accountability for end-to-end asset strategy, progression, and value realization through clinical development and toward registration.
Define and continuously evolve the integrated asset strategy, including development approach, indication prioritization, target product profile, and long-range positioning aligned to enterprise portfolio priorities.
Own the integrated business case, including financial assumptions, risk-adjusted scenarios, and value inflection points, and lead executive-level recommendations on investment, prioritization, and development pathways.
Act as the primary accountable leader in executive governance forums (e.g., GET), presenting strategic options, trade-offs, and recommendations while driving enterprise decision-making and alignment.
Operate as a peer to functional Vice Presidents, leading cross-functional alignment across Clinical, Regulatory, Manufacturing, Commercial, Finance, and Quality to ensure execution of a unified and optimized development strategy.
Drive enterprise-level trade-off decisions, balancing scientific, clinical, regulatory, operational, and financial considerations to maximize probability of success and long-term asset value.
Maintain accountability for program performance, including milestone achievement, risk profile, timeline integrity, and overall readiness for key development and regulatory inflection points.
Lead identification, evaluation, and mitigation of strategic and operational risks, ensuring proactive management and clear escalation of critical issues to executive leadership.
Provide strategic financial oversight of the program, including investment planning, scenario modeling, and alignment of resource allocation with development priorities and enterprise objectives.
Ensure consistent executive-level visibility into program status, risks, opportunities, and strategic options through structured governance and performance reviews.
Influence broader portfolio strategy and lifecycle planning, including evaluation of expansion opportunities and implications for future hematology-oncology pipeline development.
Drive a high-performance cross-functional operating model, holding stakeholders accountable for delivering against shared objectives while enabling speed, clarity, and disciplined decision-making.